N-Oleoylethanolamine - 95%, high purity , CAS No.111-58-0, Agonist of GPR119;Agonist of GPR55;Agonist of Peroxisome proliferator-activated receptor-α

Item Number
Z130746
Grouped product items
SKUSizeAvailabilityPrice Qty
Z130746-1g
1g
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$102.90
Z130746-5g
5g
2
$307.90
Z130746-25g
25g
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$1,385.90
Z130746-100g
100g
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$4,986.90

Potent PPAR-α agonist

Basic Description

SynonymsOEA | (Z)-N-(2-hydroxyethyl)octadec-9-enamide;Oleoylethanolamide | AKOS015839895 | BDBM29080 | N-Oleoyl-2-aminoethanol | N-(9Z-octadecenoyl) ethanolamine | NCGC00015761-06 | O 0383 | Oleic acid monoethanolamide | AS-15152 | HMS3412D21 | MFCD00045972 | Lop
Specifications & PurityMoligand™, ≥95%
Biochemical and Physiological MechanismsPotent PPAR-α agonist (EC 50 = 120 nM). Anandamide analog. Binds to cannabinoid receptor GPR119. Shows anti-ischemic and neuroprotective effects in vivo. Orally active.
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeAGONIST
Mechanism of actionAgonist of GPR119;Agonist of GPR55;Agonist of Peroxisome proliferator-activated receptor-α
NoteWherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
Product Description

Oleoylethanolamide (OEA) is an endogenous fatty acid ethanolamine.Small intestine cells, adipose tissues, neurons and astrocytes produces OEA.

AI Insight

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Names and Identifiers

Pubchem Sid504763464
Pubchem Sid Urlhttps://pubchem.ncbi.nlm.nih.gov/substance/504763464
IUPAC Name (Z)-N-(2-hydroxyethyl)octadec-9-enamide
INCHI InChI=1S/C20H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(23)21-18-19-22/h9-10,22H,2-8,11-19H2,1H3,(H,21,23)/b10-9-
InChi Key BOWVQLFMWHZBEF-KTKRTIGZSA-N
Canonical SMILES CCCCCCCCC=CCCCCCCCC(=O)NCCO
Isomeric SMILES CCCCCCCC/C=C\CCCCCCCC(=O)NCCO
WGK Germany 3
PubChem CID 5283454
Molecular Weight 325.529

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

5 results found

Lot NumberCertificate TypeDateItem
G2431126Certificate of AnalysisSep 19, 2023 Z130746
L2109657Certificate of AnalysisSep 19, 2023 Z130746
L2109658Certificate of AnalysisSep 19, 2023 Z130746
L2109659Certificate of AnalysisSep 19, 2023 Z130746
L2109664Certificate of AnalysisSep 19, 2023 Z130746

Safety and Hazards(GHS)

Pictogram(s) GHS07
Hazard Statements

H315:Causes skin irritation

H319:Causes serious eye irritation

H335:May cause respiratory irritation

Precautionary Statements

P261:Avoid breathing dust/fume/gas/mist/vapors/spray.

P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing.

WGK Germany 3

Related Documents

Reviews

Customer Reviews

Citations of This Product

1. Qin Yeyu, Xie Jing, Zheng Ruihe, Li Yuhang, Wang Haixia.  (2022)  Oleoylethanolamide as a New Therapeutic Strategy to Alleviate Doxorubicin-Induced Cardiotoxicity.  Frontiers in Pharmacology,  13    [PMID:35517792] [10.3389/fphar.2022.863322]

References

1. Qin Yeyu, Xie Jing, Zheng Ruihe, Li Yuhang, Wang Haixia.  (2022)  Oleoylethanolamide as a New Therapeutic Strategy to Alleviate Doxorubicin-Induced Cardiotoxicity.  Frontiers in Pharmacology,  13    [PMID:35517792] [10.3389/fphar.2022.863322]

Solution Calculators